Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CUE | PRESS-RELEASE | mixed | 6/10 | Cue Biopharma licensed global rights (ex-China) to Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases, fro | Apr 30, 2026 |
| RKDA | 10-K/A | neutral | 5/10 | Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details, | Apr 30, 2026 |
| AKBA | PRESS-RELEASE | neutral | 1/10 | Akebia Therapeutics, Inc. announced it will report its Q1 2026 results on May 7. | Apr 30, 2026 |
| IPSC | PRESS-RELEASE | neutral | 3/10 | Century Therapeutics announced an oral presentation at the ADA 86th Scientific Sessions (June 5-8, 2026) highlighting pr | Apr 30, 2026 |
| EVFM | 8-K | neutral | 4/10 | Evofem entered into a 5-year exclusive distribution agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC | Apr 30, 2026 |
| LXRX | 8-K | bearish | 6/10 | Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B Convertible Preferre | Apr 30, 2026 |
| PCRX | 8-K | neutral | 4/10 | Pacira BioSciences reported Q1 2026 revenue of $177.4M (+5% YoY) and GAAP EPS of $0.07, down from $0.10 a year ago. Non- | Apr 30, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at the Milken Institute | Apr 30, 2026 |
| HRTX | DEFA14A | neutral | 2/10 | Heron Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting scheduled for June 11, 2026. | Apr 30, 2026 |
| AXSM | PRESS-RELEASE | bullish | 8/10 | Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agitation associated wit | Apr 30, 2026 |
| DCOY | 10-K/A | neutral | 2/10 | Decoy Therapeutics filed Amendment No. 1 to its 2025 10-K to include Part III items (directors, executive compensation, | Apr 30, 2026 |
| EVOTF | 6-K | neutral | 4/10 | Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent Supervisory Board member and entered into a co | Apr 30, 2026 |
| PVCT | DEFA14A | neutral | 3/10 | Provectus Biopharmaceuticals filed DEFA14A additional definitive proxy soliciting materials on 2026-04-30. The filing co | Apr 30, 2026 |
| LYRA | 15-12G | bearish | 7/10 | Lyra Therapeutics filed a Form 15-12G to voluntarily terminate its SEC registration and suspend its reporting obligation | Apr 30, 2026 |
| CVKD | 8-K | bullish | 7/10 | Cadrenal Therapeutics announced successful completion of its End-of-Phase 2 meeting with the FDA, receiving guidance to | Apr 30, 2026 |
| CANF | 6-K | bullish | 6/10 | Can-Fite reported positive Phase 2a data for namodenoson in advanced pancreatic cancer, showing >30% stable disease, 35% | Apr 30, 2026 |
| ACRV | DEFA14A | neutral | 2/10 | Acrivon Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) for its upcoming Annual Meeting | Apr 30, 2026 |
| CYCN | 10-K/A | neutral | 3/10 | This is a routine 10-K/A amendment filed solely to include Part III items (director/officer info, executive compensation | Apr 30, 2026 |
| OPK | PRESS-RELEASE | neutral | 4/10 | OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in excha | Apr 30, 2026 |
| ENLV | PRESS-RELEASE | neutral | 4/10 | Enlivex announced that its RAIN token has been listed on the HTX cryptocurrency exchange (formerly Huobi), one of the to | Apr 30, 2026 |
| QNRX | PRESS-RELEASE | neutral | 1/10 | Quoin Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 30, 2026 |
| TOMZ | PRESS-RELEASE | mixed | 6/10 | TOMI Environmental Solutions announced a non-binding LOI to merge with Carbonium Core, a nuclear-grade graphite producer | Apr 30, 2026 |
| OGN | DEFA14A | neutral | 3/10 | Organon filed this DEFA14A as additional soliciting material in support of its pending acquisition by Sun Pharma for $14 | Apr 30, 2026 |
| NCEL | PRESS-RELEASE | bearish | 6/10 | NewcelX reported FY2025 results with a net loss of $8.3M (including $5.7M non-cash finance expenses) and cash of $2.2M. | Apr 30, 2026 |
| HALO | 8-K | neutral | 3/10 | Halozyme appointed Darren Snellgrove as permanent CFO, effective June 8, 2026, replacing interim CFO David Ramsay who wi | Apr 30, 2026 |
| PRQR | 6-K | neutral | 2/10 | ProQR announced the nomination of Dr. Lykke Hinsch Gylvin, CMO of Boehringer Ingelheim, to its Board of Directors, subje | Apr 30, 2026 |
| LXRX | PRESS-RELEASE | neutral | 1/10 | Lexicon Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 30, 2026 |
| INMB | PRESS-RELEASE | neutral | 1/10 | INmune Bio, Inc. announced it will report its Q1 2026 results on May 7. | Apr 30, 2026 |
| PRQR | PRESS-RELEASE | neutral | 2/10 | ProQR announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Bo | Apr 30, 2026 |
| BAK | 6-K | bearish | 7/10 | Braskem S.A. filed the minutes of its Annual General Meeting held on April 29, 2026, which approved the FY2025 financial | Apr 30, 2026 |